Pivotal Trial for a Synthetic Tissue Substitute for Concealment of Artificial Ocular Implants

Glaucoma Eye Clinical Trial

— EverPatch  

Official title:

A Single Arm, Pivotal, Open Label, Multi-centre Clinical Investigation to Evaluate the Clinical Safety and Performance of the CorNeat EverPatch, A Synthetic Tissue Substitute for Concealment of Artificial Ocular Implants

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05469867
• Other study ID #: DMS-34948
• Status: Active, not recruiting
• Phase: N/A
• Start date: August 16, 2022
• Est. completion date: March 1, 2024

Study information

• Verified date: February 2023
• Source: CorNeat Vision Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical trial will assess the clinical safety and performance of the CorNeat EverPatch device used as a tissue substitute for concealment of artificial ocular implants.

Description:

A single arm, pivotal, open label, multi-centre clinical investigation to evaluate the clinical safety and performance of the CorNeat EverPatch, a synthetic tissue substitute for concealment of artificial ocular implants. Subjects will sign a consent form and will be assessed for eligibility based on clinical examinations and medical history. Upon eligibility verification, subjects will be implanted with the investigational device as part of an ophthalmic surgery in which a concealment of an artificial implant is required. Clinical examinations at follow up will include slit lamp biomicroscopy, assessment of visual acuity and intra ocular pressure, and recording of concomitant medications and any safety issues. Follow up visits will be performed at 1 week, 1-, 2-, 3-, 6-, 9- and 12-months post-op.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 60
• Est. completion date: March 1, 2024
• Est. primary completion date: March 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Male or female

2. Aged = 18 and = 80 years on screening day

3. Concealment of glaucoma tube shunt or suture tags is indicated

4. Patients with viable and intact conjunctiva

5. Candidates must have the ability and willingness to provide a written informed consent, attend all scheduled visits and comply with study procedures

6. Adequate tear film and lid function as indicated by Tear Film Breakup Time test - more than 5 seconds

7. Visual acuity of light perception or better

8. Female patients of childbearing age must agree to use an acceptable and effective method of contraception throughout the study, including the follow-up period, and have negative pregnancy test at screening.

Exclusion Criteria:

1. Current retinal detachment

2. Active ocular or orbital infection

3. History or evidence of severe inflammatory eye diseases (i.e. uveitis, retinitis, scleritis) in one or both eyes within 6 months prior to planned implantation

4. History of ocular or periocular malignancy

5. History of extensive keloid formation

6. Any known intolerance or hypersensitivity to topical anesthetics, mydriatics, or component of the device, specifically Oxybuprocaine hydrochloride, lidocaine, tropicamide, epinephrine, Iodine solution & aromatic polycarbonate urethane

7. Signs of current infection, including fever and current treatment with antibiotics

8. Severe generalized disease that results in a life expectancy shorter than a year

9. Any clinical evidence that the investigator feels would place the subject at increased risk with the placement of the device

10. Pregnant or breastfeeding female subjects

11. Participation in any study involving an investigational drug or device within 30 days of the study or 5 half-lives of the drug (whichever longer) or ongoing participation in a study with an investigational drug or device

12. Any traumatic perforation of the globe OR tissue gaps/weaknesses, resulting either from traumatic, disease- related or iatrogenic damage OR loss of scleral integrity where use of tissue or substitutes is indicated

13. Vulnerable populations

14. Active drug or alcohol abuse or dependence that, in the opinion of the principle investigator, would interfere with adherence to study requirements

15. Subjects with other concurrent severe and/or uncontrolled medical condition which could compromise participation in the study (e.g. active infection, uncontrolled diabetes, uncontrolled hypertension, congestive heart failure, unstable angina, ventricular arrhythmias, active ischemic heart disease, myocardial infarction within six months, uncompensated cirrhosis, active upper GI tract ulceration, active inflammatory disease, malignancy under active treatment)

16. Subjects who receive anti-coagulation treatment which cannot be interfered during the perioperative period

17. Hemoglobin A1C (HbA1c) higher than 8% at screening indicating unbalanced diabetes and/or target organ damage associated with diabetes

18. Subjects receiving chronic systemic immunosuppressants (e.g. steroids, cyclosporine etc.)

Related Conditions & MeSH terms

• Glaucoma
• Glaucoma Eye
• Tissue Breakdown

Intervention

Device:
• CorNeat EverPatch
The CorNeat EverPatch will be implanted subconjunctivally over an ocular implant (e.g. glaucoma shunt, exposed suture tags) and fixed to the eye wall. The overlying conjunctiva will be closed over the patch.

Locations

Country	Name	City	State
Canada	EyeCare Miramichi Eye NB	Miramichi
Canada	Prism Eye Institute	Oakville
Canada	University Health Network	Toronto
France	Hôpital Fondation Rothschild	Paris
Georgia	DaVinci Eye Care	Tbilisi

Sponsors (1)

Lead Sponsor	Collaborator
CorNeat Vision Ltd.

Countries where clinical trial is conducted

Canada,  France,  Georgia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety Assessment	The frequency of all Unanticipated Adverse Device-related Events (UADE) during and following implantation will be recorded	Up to 12 months
Secondary	Performance Assessment	Tube or suture exposure will be detected by slit-lamp Biomicroscopy throughout the entire follow up period and incidence will be calculated. Prevention of tube or suture exposure associated with conjunctival erosion and graft melting should be demonstrated in at least 90% of the patients.	6 & 12 months post-op.